Moderna Strengthens Production in Spain to Reach 500 Million Doses by 2022

Moderna strengthens its alliance in Spain. The U.S. biotech company, which has an agreement in the country with Laboratorios Farmacéuticos Rovi, expects to end 2022 by manufacturing 500 million doses of its anti-Covid-19 vaccine, Juan Carlos Gil, Moderna’s general manager in Spain and Portugal, confirmed.

So far, the company has manufactured just over 350 million doses of its Covid-19 vaccine in Spain, which it has distributed to more than sixty countries. On a global scale, these 500 million doses translate into more than 800 million doses, plans which in Spain are forged with the renewal of the agreement between Moderna and Rovi for a further ten years to increase the formulation, aseptic filling, inspection, labeling and packaging capacities at Rovi’s facilities in Madrid, San Sebastián de los Reyes and Alcalá de Henares.

This new agreement includes anchoring the production of Moderna’s Covid-19 vaccine at Rovi’s factories. In addition, the Spanish company’s platform may also be used to service Moderna’s future messenger RNA (mRNA) vaccine candidates.

Read more about Moderna and find the most important business headlines of the day with the Born2Invest mobile app. Our companion app keeps its readers up to date with the latest market updates for free.

The biotech company strengthens its production in Spain to reach 500 million doses by 2022

mRNA serves as a starting point for multiple new projects that Moderna is working on. The biotech company aims to have a pan-respiratory vaccine. “Respiratory viruses cause the most deaths; when a patient is admitted to the hospital with a serious illness, what finally causes death is a respiratory condition,” explained Gil. And from respiratory viruses to the bivalent influenza-Covid: presumably, by the end of 2023 Spain will be able to distribute a vaccine of this type with Moderna’s seal of approval, which will be able to prevent hospitalizations and deaths. Another of Moderna’s challenges is to find a vaccine capable of eradicating the fifteen pathogens that the World Health Organization (WHO) considers most dangerous to public health.

“We want a vaccine to enter the clinical trial phase by 2025,” said the head of Moderna in Spain. Some of these diseases are malaria, Zika, dengue, tuberculosis, HIV, and Crimean-Congo hemorrhagic fever.

Moderna closed 2021 with a profit of $12.2 billion

The company closed 2021 with a profit of $12.2 billion, compared to a loss of $747 million recorded in 2020.

Moderna’s total revenue in 2021 was $18.471 billion, compared with $803 million in 2020. Of this total amount, product sales were $17.675 million, compared with $200 million in 2020. The biotech company believes that the Sars-Cov-2 virus will evolve into an endemic phase in 2022 and, as a result, the company expects sales to be higher in the second half than in the first half of the year.

In 2022, the company plans to further expand its commercial network by establishing or activating commercial subsidiaries in the following regions: in Asia: Hong Kong, Malaysia, Singapore, and Taiwan; and in Europe: Belgium, Denmark, and the Netherlands, Norway, Poland, and Sweden. In addition, Moderna will continue to work with distributors or partners in other geographies.

__

(Featured image by torstensimon via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.